Document is current

Article History

Received: 10 May 2023

Revised: 31 August 2023

Accepted: 6 September 2023

First Online: 26 September 2023

Declarations

:

: YC has received honoraria from Chugai Pharmaceuticals, Sanofi Genzyme, Bayer, Takeda Pharmaceutical, Novo Nordisk Pharma, Pfizer, KM Biologics, Japan Blood Products Organization, Fujimoto Pharmaceuticals and CSL-Behring. KA has received research grants from KM Biologics and also honoraria from Chugai Pharmaceuticals, Sanofi Genzyme, Bayer, Takeda Pharmaceutical, Novo Nordisk Pharma, Pfizer, KM Biologics, Japan Blood Products Organization and CSL-Behring. KS was an endowed Assistant Professor funded by Baxter/Baxalta/Shire and CSL-Behring until March 2020. MB has received funding for research as a Principle Investigator from Chugai Pharmaceuticals, and also honoraria from Chugai Pharmaceuticals, Sanofi Genzyme, Bayer, Takeda Pharmaceutical, Novo Nordisk Pharma, Pfizer, KM Biologics, and CSL-Behring. RM has received honoraria from Chugai Pharmaceutical, Sanofi, Bayer, Takeda Pharmaceutical and CSL-Behring. TY has received honoraria from Chugai Pharmaceuticals, Novo Nordisk Pharma, Bayer, Kyowa Hakko Kirin and Sanofi Genzyme. AM is the holder of an endowed chair at the Department of Gene Research of Coagulation Disorders at Tokyo Medical University, which received funding from CSL-Behring. HI has received speaker honoraria from Sanofi and CSL-Behring. TH has received research grant from Sanofi Genzyme, and also honoraria from Chugai Pharmaceuticals, Sanofi Genzyme, Bayer, Takeda Pharmaceutical, Novo Nordisk Pharma, Pfizer, KM Biologics, Japan Blood Products Organization and CSL-Behring. EK has received research grants from Chugai Pharmaceuticals and CSL-Behring, and also received honoraria from Chugai Pharmaceuticals, Sanofi Genzyme, Bayer, Takeda Pharmaceutical, Novo Nordisk Pharma, and CSL-Behring.